Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 29.08
NVIV's Cash to Debt is ranked lower than
53% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. NVIV: 29.08 )
Ranked among companies with meaningful Cash to Debt only.
NVIV' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 40.89 Max: No Debt
Current: 29.08
F-Score: 4
Z-Score: 15.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -119.26
NVIV's ROE (%) is ranked lower than
86% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. NVIV: -119.26 )
Ranked among companies with meaningful ROE (%) only.
NVIV' s ROE (%) Range Over the Past 10 Years
Min: -775.86  Med: -325.82 Max: -30.97
Current: -119.26
-775.86
-30.97
ROA (%) -81.60
NVIV's ROA (%) is ranked lower than
83% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. NVIV: -81.60 )
Ranked among companies with meaningful ROA (%) only.
NVIV' s ROA (%) Range Over the Past 10 Years
Min: -1218.1  Med: -233.77 Max: 42.86
Current: -81.6
-1218.1
42.86
ROC (Joel Greenblatt) (%) -2146.26
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. NVIV: -2146.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVIV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3330.38  Med: -1661.69 Max: 334.39
Current: -2146.26
-3330.38
334.39
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

NVIV Guru Trades in

NVIV Guru Trades in

NVIV Guru Trades in

Q1 2016

NVIV Guru Trades in Q1 2016

Jim Simons 31,700 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:TBRA, NAS:MNOV, NAS:CYNA, NAS:RGNX, NAS:FLKS, NAS:PTI, NAS:CRIS, NAS:CCXI, NAS:FOMX, OTCPK:OXBDF, NAS:IDRA, NAS:ENZY, NAS:VTL, AMEX:MDGN, NAS:CBMG, NAS:RXDX, NAS:CYAD, NAS:BCRX, OTCPK:EYRYY, NAS:PRTK » details
Traded in other countries:04IA.Germany,
InVivo Therapeutics Holdings Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.

Ratios

vs
industry
vs
history
P/B 5.08
NVIV's P/B is ranked lower than
67% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. NVIV: 5.08 )
Ranked among companies with meaningful P/B only.
NVIV' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 67.4
Current: 5.08
0
67.4
Current Ratio 9.76
NVIV's Current Ratio is ranked higher than
75% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. NVIV: 9.76 )
Ranked among companies with meaningful Current Ratio only.
NVIV' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.70 Max: 14.81
Current: 9.76
0.14
14.81
Quick Ratio 9.76
NVIV's Quick Ratio is ranked higher than
76% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. NVIV: 9.76 )
Ranked among companies with meaningful Quick Ratio only.
NVIV' s Quick Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.70 Max: 14.81
Current: 9.76
0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.33
NVIV's Price/Net Cash is ranked lower than
51% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. NVIV: 5.33 )
Ranked among companies with meaningful Price/Net Cash only.
NVIV' s Price/Net Cash Range Over the Past 10 Years
Min: 4.72  Med: 17.21 Max: 48
Current: 5.33
4.72
48
Price/Net Current Asset Value 5.21
NVIV's Price/Net Current Asset Value is ranked lower than
54% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. NVIV: 5.21 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVIV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.44  Med: 16.52 Max: 34.94
Current: 5.21
4.44
34.94
Price/Tangible Book 5.08
NVIV's Price/Tangible Book is ranked lower than
59% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. NVIV: 5.08 )
Ranked among companies with meaningful Price/Tangible Book only.
NVIV' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.83  Med: 14.02 Max: 29.63
Current: 5.08
3.83
29.63
Earnings Yield (Greenblatt) (%) -14.30
NVIV's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. NVIV: -14.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVIV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -45.99  Med: 0.00 Max: 1000
Current: -14.3
-45.99
1000

More Statistics

EPS (TTM) $ -0.89
Beta3.44
Short Percentage of Float9.57%
52-Week Range $3.50 - 17.19
Shares Outstanding (Mil)31.91

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.08 -1.16 -0.89
EPS w/o NRI ($) -1.08 -1.16 -0.89
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NVIV

Headlines

Articles On GuruFocus.com

More From Other Websites
Coverage initiated on InVivo Therapeutics by Ladenburg Thalmann Jul 21 2016
InVivo Therapeutics Announces Ben Taub Hospital/Baylor College of Medicine as New Site for INSPIRE... Jul 18 2016
InVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study Jul 14 2016
InVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study Jul 14 2016
InVivo Therapeutics Receives Investigational Testing Authorization from Health Canada Jul 13 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial... Jul 13 2016
InVivo Therapeutics Receives Investigational Testing Authorization from Health Canada Jul 13 2016
InVivo Therapeutics Announces Update on the INSPIRE Study and FDA Approval of Expansion of the Study... Jul 12 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial... Jul 12 2016
InVivo Therapeutics Announces Update on the INSPIRE Study and FDA Approval of Expansion of the Study... Jul 12 2016
InVivo Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 08 2016
InVivo Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 08 2016
InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society Jun 23 2016
InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society Jun 23 2016
InVivo Therapeutics Announces Publication in Neurosurgery of Case Report Detailing First... Jun 22 2016
InVivo Therapeutics Announces Publication in Neurosurgery of Case Report Detailing First... Jun 22 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers Jun 08 2016
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors Jun 08 2016
InVivo Therapeutics Announces Appointment of Christina Morrison to its Board of Directors Jun 08 2016
Invivo Therapeutics Holdings Corp. :NVIV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6,... Jun 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)